Luththera: Funding update for radionuclide therapy for pancreatic neoroendocrine tumours (pNETs). Effective November 7, 2023, Ontario Health will fund the use of Lutathera to treat eligible pancreatic neuroendocrine tumour (pNETs) [...]
One step closer to access to Lutathera for pNETs patients! The pan-Canadian Pharmaceutical Alliance (pCPA) negotiations with Advanced Accelerator Applications for Lutathera (lutetium 177 dotatate) in pNETs concluded on [...]
Are you looking for a unique leadership opportunity? Have you been yearning to put your talent in strategic thinking, financial analysis, project management, communications or policy advocacy in the [...]
Ipsen announces investment in new state-of-the-art electronic autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) designed to improve patient experience. New electronic autoinjector is designed to improve patient experience for [...]